Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile Unknown unknown
Therapy Bevacizumab + Capecitabine + Paclitaxel
Indication/Tumor Type triple-receptor negative breast cancer
Response Type not applicable


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown triple-receptor negative breast cancer not applicable Bevacizumab + Capecitabine + Paclitaxel Phase II Actionable In a Phase II clinical trial, treatment with the combination of Avastin (bevacizumab), Xeloda (capecitabine), and Taxol (paclitaxel) resulted in an overall response rate of 77% (44/57), including complete response in 19% (11/57), and a median progression-free survival of 7.6 months and median overall survival of 19.2 months in patients with triple-negative breast cancer (PMID: 27412268). 27412268
PubMed Id Reference Title Details
(27412268) Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study. Full reference...